HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risk of Acute Cerebrovascular and Cardiovascular Events Among Users of Acetaminophen or an Acetaminophen-Codeine Combination in a Cohort of Patients with Osteoarthritis: A Nested Case-Control Study.

AbstractSTUDY OBJECTIVE:
To determine whether acetaminophen or an acetaminophen-codeine combination is associated with an increased risk of acute cerebrovascular and cardiovascular events (ACCEs) in patients with osteoarthritis.
DESIGN:
Nested case-control study.
DATA SOURCE:
Health Search IMS Health Longitudinal Patient Database.
PATIENTS:
A total of 36,754 adults with a diagnosis of osteoarthritis and an incident (first-time) prescription of nonsteroidal antiinflammatory drugs (NSAIDs) between January 2002 and June 2012 were identified; of these patients, cases were defined as those who had a diagnosis of an ACCE during the follow-up period (index date was the date of ACCE diagnosis; 2182 cases). For each case, up to five controls were randomly selected who were matched based on age, sex, month and year of cohort entry, and duration of follow-up (10,301 controls). Matched controls were assigned the same index date as their respective cases.
MEASUREMENTS AND MAIN RESULTS:
For each case and matched controls, all prescriptions of acetaminophen-containing medicines filled during follow-up were identified. The risk of ACCEs was investigated with respect to the recency of use of acetaminophen and/or an acetaminophen-codeine combination. Patients were classified as current (0-90 days preceding index date), recent (91-180 days), or past (181-365 days) acetaminophen users, or nonusers (longer than 365 days), with nonusers representing the reference category. Conditional logistic regression was estimated to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Of the 36,754 patients with osteoarthritis and newly prescribed NSAIDs, the incidence rate of ACCEs was 117.6 per 10,000 person-years. No significant association between exposure to acetaminophen-containing medications and ACCEs was observed in current (OR 1.22, 95% CI 0.96-1.55), recent (OR 1.12, 95% CI 0.80-1.55), or past users (OR 1.13, 95% CI 0.86-1.48). A secondary analysis evaluating exposure to acetaminophen monotherapy or acetaminophen-codeine combination therapy showed similar results for current users.
CONCLUSION:
Our findings indicate that no association can be made between the use of acetaminophen and/or an acetaminophen-codeine combination and the occurrence of ACCEs. This information contributes to support clinicians in the choice of acetaminophen therapy for osteoarthritis-related pain, especially in those patients presenting with cerebrovascular and cardiovascular morbidities or related risk factors.
AuthorsGiuseppe Roberto, Monica Simonetti, Carlo Piccinni, Pier Lora Aprile, Iacopo Cricelli, Andrea Fanelli, Claudio Cricelli, Francesco Lapi
JournalPharmacotherapy (Pharmacotherapy) Vol. 35 Issue 10 Pg. 899-909 (Oct 2015) ISSN: 1875-9114 [Electronic] United States
PMID26497476 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 Pharmacotherapy Publications, Inc.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Drug Combinations
  • acetaminophen, codeine drug combination
  • Acetaminophen
  • Codeine
Topics
  • Acetaminophen (administration & dosage, adverse effects, therapeutic use)
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
  • Cardiovascular Diseases (epidemiology)
  • Case-Control Studies
  • Cerebrovascular Disorders (epidemiology)
  • Codeine (administration & dosage, adverse effects, therapeutic use)
  • Cohort Studies
  • Drug Combinations
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Osteoarthritis (drug therapy)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: